Prof. Qi Zhou 周琦
Chief Physician, Professor
Gynecologic Oncology Center, Chongqing University Cancer Hospital, Chongqing
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis and treatment of benign and malignant gynecologic tumors, including chemotherapy, radiotherapy, and surgery. Focus on screening, early diagnosis, standardized care, ovarian cancer early detection, cervical cancer prevention, and precancerous lesion intervention.
Dr. Zhou is a Chief Physician, Professor, and Doctoral Supervisor with 30 years of experience in gynecologic oncology. Dr. Zhou serves as Director of Chongqing University Cancer Hospital and leads research on ovarian and cervical cancer early diagnosis. Dr. Zhou has led over 10 national and provincial research projects, published more than 70 papers, and holds editorial roles at several medical journals.
Professional roles
- Standing Committee Member, Chinese Medical Association
- Executive Director, China Anti-Cancer Association
- Chair-elect, Gynecologic Oncology Committee, China Anti-Cancer Association
- Standing Committee Member, Oncology Branch, Chinese Medical Doctor Association
Name order: in Chinese the family name comes first (Zhou Qi). Papers usually list the name as Qi Zhou or Zhou Q.
Selected publications
65 papers on PubMed matched by name and affiliation; 22 as first or senior author since 2016. Most recent first- or senior-author papers:
- Cancer Med, 2026 (senior author): Safety, Tolerability, and Pharmacokinetics of Mirvetuximab Soravtansine in Chinese Patients With Folate Receptor α-Positive Advanced Ovarian Cancer. PubMed 42165281
- PeerJ, 2026 (senior author): Development and validation of a risk prediction model for overall survival in cervical cancer patients under 50: a prospective cohort study in southwest China. PubMed 41522516
- Cancer Cell Int, 2025 (senior author): A Chinese prospective cohort research developed and validated a risk prediction model for patients with cervical cancer. PubMed 40223085
- J Natl Cancer Cent, 2025 (senior author): Corrigendum to 'Efficacy and safety of paclitaxel liposome versus paclitaxel in combination with carboplatin in the first-line chemotherapy for ovarian cancer: a multicenter, open-label, non-inferiority, randomized controlled trial' [Journal of the National Cancer Center 4 (2024) 135-141]. PubMed 40040875
- Gynecol Oncol, 2025 (senior author): Multicenter study of ovarian cancer score for diagnosing ovarian cancer. PubMed 39793443
- J Natl Cancer Cent, 2024 (senior author): Efficacy and safety of paclitaxel liposome versus paclitaxel in combination with carboplatin in the first-line chemotherapy for ovarian cancer: a multicenter, open-label, non-inferiority, randomized controlled trial. PubMed 39282588
- Genes Dis, 2023 (senior author): Development of a molecular feature-based survival prediction model of ovarian cancer using the deep neural network. PubMed 37397532
- Cell Signal, 2023 (senior author): The myo-inositol biosynthesis rate-limiting enzyme ISYNA1 suppresses the stemness of ovarian cancer via Notch1 pathway. PubMed 37105506
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion